Introducing PBPK Nexus, our plans, our future.
Chara Litou, Certara
Session: Special Populations
Session Chair: Loeckie De Zwart & Pieter Annaert
PBPK Modeling to support dosing and Risk Assessment in Pregnancy and Lactation
Sophie Fischer, ESQLabs
Lactation PBPK: Impact of CYP2D6 phenotype on Fluoxetine
Amita Pansari, Certara
Predicting Cefixime exposure during pregnancy using PBPK
Simon Koele, Radboud University
PBPK modeling of the impact of Organ impairment on PK
Agustos Ozbey, Idorsia
PBPK modeling of Elexacaftor, Tezacaftor, and Ivacaftor to predict clinical DDI and impact on moderate Hepatic Impairment Population
Jiangfan Wu, University Munich
PBPK modelling to investigate the impact of hepatic impairment on the pharmacokinetics of biologics
Felix Stader, Certara
Session: Biomarkers / Disease
Session Chair: Maxime Le Merdy & Abla Nada Geiser
Bilirubin metabolism in health and disease and its comparison with RWD
Ahenk Zeynep Sayin, University Hospital Aachen
GI Tissue exposures Crohn’s Disease
Simon Teague, Pharmaron
LAI in Obesity
Mattia Berton, Roche
Rapid Fire Oral Presentations 5 mins each.
Session: Biologics
Session Chair: Neil Parrott & Pradeep Sharma
Application of PBPK for long-acting peptide therapeutics
Howard Burt, Novo Nordisk
PBPK of tumor targeting bispecific mAbs
Armin Sepp, Certara
PBPK of Subcutaneous Absorption for mAbs
Erik Sjoegren, Uppsala
Download the full program
PBPK Conference 2026 